选择性COX-2抑制剂尼美舒利抑制胃癌细胞株SGC7901端粒酶的活性

Nimsulide suppresses the telomerase activity of SGC7901 gastric cancer cell line

目的:探讨选择性COX-2抑制剂尼美舒利对胃癌细胞株SGC7901细胞增生及端粒酶活性的影响,为选择性COX-2抑制剂应用于胃癌的防治提供新的理论依据.方法:用不同浓度的尼美舒利(0,50,100,200及400μmol/L)处理SGC7901胃癌细胞株后,采用MTT比色试验和PCR-ELSIA半定量法检测细胞的增生和端粒酶活性,同时用相差显微镜动态观察细胞形态及生长方式上的改变.结果:尼美舒利呈时间剂量依赖性抑制SGC7901细胞的生长,同时他也能显著抑制SGC7901细胞的端粒酶的活性,50,100,200及400μmol/L浓度的尼美舒利实验组的吸光度值分别为2.12±0.11,1.54±0.08,1.13±0.09,0.79±0.12vs2.76±0.06(P<0.01),并呈剂量依赖关系.结论:选择性COX-2抑制剂尼美舒利能抑制胃癌细胞株SGC7901的端粒酶活性,进而抑制其细胞生长,这也可能是选择性COX-2抑制剂抗肿瘤作用的又一新的机制.

AIM:To investigate whether nimsulide,a COX-2-specific inhibitor, could inhibit the proliferation viability and the telomerase activity of SGC7901 gastric cancer cell line. METHODS:After SGC7901 was treated with different con- centrations of nimsulide (0, 50, 100, 200 and 400 μmol/L, respectively), the cellular proliferation was evaluated by MTT assay and the telomerase activity was detected by PCR- ELISA assay.And the cell morphology and growth manner were observed under phase contrast microscope. RESULTS:Nimsulide could inhibit the growth of SGC7901 gastric cancer cell line in the time and dose-dependent manner; and the telomerase activity of SGC7901 was sig- nificantly lower in the 50, 100, 200 and 400 μmol/L groups than that in the control group, their absorbance values were 2.12±0.11,1.54±0.08,1.13±0.09, 0.79±0.12 vs 2.76±0.06 (P <0.01), respectively. CONCLUSION:COX-2-specific inhibitor could inhibit the telomerase activity of gastric cancer cell line, which pro- vides a new pathway of COX-2-specific inhibitor in inhibit- ing the growth of gastric cancer.